Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
116076 trials found · Page 432 of 5804
-
New vaccine combo takes on tough cancers
Disease control Recruiting nowPhase 1b study evaluating the efficacy and immune response to a synthetic long peptide mutant KRAS vaccine (SPL mKRASvax) combined with Balstilimab and Botensilimab for unresectable or metastatic mismatch repair-proficient (MMR-p) colorectal cancer (mCRC) or unresectable or metas…
Phase: PHASE1 • Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins • Aim: Disease control
Last updated Jun 27, 2026 08:05 UTC
-
Could a daily pill replace infusions for MS? new trial aims to find out
Disease control Recruiting nowThe purpose of this Phase 3b study is to assess the efficacy, safety and tolerability of remibrutinib after switching from ocrelizumab and compared to continuous ocrelizumab treatment, in patients living with relapsing multiple sclerosis (plwRMS).
Phase: PHASE3 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 28, 2026 00:00 UTC
-
New drug combo aims to halt blindness from 'Dry' macular degeneration
Disease control Recruiting nowA Phase 2, Randomized, Placebo-controlled, Multicenter, Masked Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacodynamics of Multidose APL-3007 in Combination with Syfovre/Pegcetacoplan (APL-2) in Patients Diagnosed with Geographic Atrophy Secondary to Age-Related…
Phase: PHASE2 • Sponsor: Apellis Pharmaceuticals, Inc. • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
Can two common compounds supercharge CAR-T against myeloma?
Disease control Recruiting nowThis phase II trial tests how well giving dasatinib and quercetin with cyclophosphamide, fludarabine and chimeric antigen receptor (CAR)-T cell therapy works in treating patients with multiple myeloma that has come back after a period of improvement (relapsed) or that has not res…
Phase: PHASE2 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated Jun 27, 2026 09:02 UTC
-
Precision radiation boost aims to outsmart deadly brain cancer
Disease control Recruiting nowGlioblastoma (GBM) is the most common primary brain cancer in adults. Surgery, chemoradiotherapy (temozolomide TMZ) and then adjuvant TMZ is the standard treatment. But, most patients relapse in a median time of 8-9 months; the median overall survival (OS) ranged from 15 to 18 mo…
Phase: PHASE2 • Sponsor: Centre Paul Strauss • Aim: Disease control
Last updated Jun 27, 2026 09:02 UTC
-
New drug aims to cut COPD Flare-Ups in patients with type 2 inflammation
Disease control Recruiting nowDepemokimab is being developed as a treatment for individuals with moderate to severe COPD. The aim of this study is to assess the efficacy and safety of depemokimab compared as an add-on medicine in participants with uncontrolled moderate to severe COPD with type 2 inflammation.
Phase: PHASE3 • Sponsor: GlaxoSmithKline • Aim: Disease control
Last updated Jun 27, 2026 12:05 UTC
-
Drop of blood could spot deadly poison in minutes
Diagnosis Recruiting nowMethanol poisoning is a serious issue, particularly in low- and middle-income countries (LMICs), where outbreaks can devastate communities. Diagnosing methanol poisoning is challenging because its symptoms mimic many other conditions, and traditional diagnostic methods require ex…
Sponsor: University of Edinburgh • Aim: Diagnosis
Last updated Jun 27, 2026 12:01 UTC
-
New drug trial aims to boost survival in severe lung failure patients
Disease control Recruiting nowThis is a Phase 2 multicenter, randomized, double-blinded, placebo-controlled study that will evaluate the safety and efficacy of host-directed therapeutics in hospitalized adults diagnosed with Acute Respiratory Distress Syndrome (ARDS) utilizing a platform trial design. Cohort…
Phase: PHASE2 • Sponsor: PPD Development, LP • Aim: Disease control
Last updated Jun 27, 2026 12:30 UTC
-
Dogs sniff out bladder cancer in urine samples
Diagnosis Recruiting nowThe aim of this study is to estimate the sensitivity of olfactory detection of urothelial carcinomas of the bladder in urine samples by assistance dogs trained in this practice.
Sponsor: University Hospital, Strasbourg, France • Aim: Diagnosis
Last updated Jun 27, 2026 08:10 UTC
-
Jail-to-Community opioid treatment: monthly shot vs. daily pill
Disease control Recruiting nowThis study is an open label randomized controlled trial of extended-release buprenorphine (BRIXADI, XR-B) vs. sublingual buprenorphine (SL-B) in a large metropolitan jail. An open-label design will randomly assign 240 adults with moderate-to-severe OUDs who are soon-to-be-release…
Phase: PHASE3 • Sponsor: Friends Research Institute, Inc. • Aim: Disease control
Last updated Jun 27, 2026 13:03 UTC
-
New hope for stomach cancer: targeted drug combo under study
Disease control Recruiting nowThe primary objective is to validate, throughout a national real-world study, the efficacy and safety of Zolbetuximab combined with FOLFOX or XELOX regimens. Specific clinical issues will be studied by pre-planned subgroup analyses, addressing practical clinical needs which have …
Sponsor: European Institute of Oncology • Aim: Disease control
Last updated Jun 27, 2026 09:08 UTC
-
New combo therapy takes on bulky tumors
Disease control Recruiting nowStudy Objectives Primary Objective:To evaluate the safety of SFRT followed by hypofractionated/conventional fractionated radiotherapy combined with Iparomlimab and Tuvonralimab Injection in relapsed/refractory bulky solid tumors. Secondary Objectives:To assess efficacy (objectiv…
Phase: PHASE2 • Sponsor: Second Affiliated Hospital of Nanchang University • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
Two new drugs join forces with chemo to tackle tough lymphoma
Disease control Recruiting nowThis study is developed by the investigator and is a, phase I, single arm, clinical trial that will enroll subjects with untreated diffuse large B-cell lymphoma (DLCBL) at high risk for poor outcome. The types of treatments given will be shared with participants. The aims are: …
Phase: PHASE1 • Sponsor: The University of Texas Health Science Center at San Antonio • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
Engineered immune cells take aim at childhood cancer
Disease control OngoingThis is a first in human dose escalation trial to determine the safety of administering PHOX2B PC-CAR T cells in patients with advanced, high-risk neuroblastoma.
Phase: PHASE1 • Sponsor: Stephan Grupp MD PhD • Aim: Disease control
Last updated Jul 03, 2026 00:00 UTC
-
Immune cell reprogramming offers hope for stubborn arthritis and Sjogren's
Disease control Recruiting nowA study to assess safety, cellular kinetics and exploratory efficacy of rapcabtagene autoleucel in rheumatoid arthritis and Sjogren's disease
Phase: PHASE1, PHASE2 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 12:38 UTC
-
New drug aims to cut dangerous COPD attacks in half
Disease control Recruiting nowDepemokimab is being developed as a treatment for individuals with moderate to severe COPD. The aim of this study is to assess the efficacy and safety of depemokimab as an add-on medicine in participants with uncontrolled moderate to severe COPD with type 2 inflammation.
Phase: PHASE3 • Sponsor: GlaxoSmithKline • Aim: Disease control
Last updated Jun 27, 2026 07:53 UTC
-
Cell injection aims to slow vision loss in rare eye disease
Disease control Recruiting nowThis study evaluates the safety of a single injection of jCell (famzeretcel) comprising 6.0 million (6.0M) retinal progenitor cells over a six-month study period in a cohort of adult subjects with RP. Additionally, changes in visual function will be evaluated at six months betwee…
Phase: PHASE2 • Sponsor: jCyte, Inc • Aim: Disease control
Last updated Jun 27, 2026 12:06 UTC
-
New mesh device could seal brain aneurysms, avoid surgery
Disease control Recruiting nowThe objective of the Safety and Efficacy of Endovascular Treatment of Intracranial Aneurysms with Surpass Elite with GUARDian Flow Diverter (GUARD) trial is to evaluate the safety and efficacy of the Surpass Elite with Guardian Flow Diverter System (FDS) in the treatment of unrup…
Phase: NA • Sponsor: Stryker Neurovascular • Aim: Disease control
Last updated Jun 27, 2026 12:05 UTC
-
Biomarker-Guided cocktail aims to slow kidney failure
Disease control Recruiting nowOver 800 million people worldwide suffer from chronic kidney disease (CKD), which is associated with a high individual disease burden for those affected, multiple secondary diseases, frequent doctor contacts, and hospitalizations, but also outstanding costs for the health system …
Phase: PHASE4 • Sponsor: Peter Rossing • Aim: Disease control
Last updated Jun 27, 2026 07:58 UTC
-
Experimental combo aims to control MDS without transplant
Disease control Recruiting nowThis study aims to evaluate the safety and efficacy of a Venetoclax and hypomethylating agent-based regimen combined with infusion of HLA-mismatched donor G-CSF mobilized peripheral blood mononuclear cells (GPBMC) in patients with intermediate-risk and higher myelodysplastic synd…
Phase: PHASE2 • Sponsor: Beijing 302 Hospital • Aim: Disease control
Last updated Jun 27, 2026 07:59 UTC